JIUN-KAE JACK LEE to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Randomized Controlled Trials as Topic.
Connection Strength
1.534
-
Commentary on Hey and Kimmelman. Clin Trials. 2015 Apr; 12(2):110-2.
Score: 0.272
-
Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res. 2012 Sep 01; 18(17):4498-507.
Score: 0.228
-
Bayesian adaptive randomization designs for targeted agent development. Clin Trials. 2010 Oct; 7(5):584-96.
Score: 0.198
-
A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol. 2010 Jun 05; 10:48.
Score: 0.197
-
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials. 2008; 5(3):181-93.
Score: 0.167
-
Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol. 2005 Jul 01; 23(19):4450-7.
Score: 0.140
-
A Bayesian decision-theoretic sequential response-adaptive randomization design. Stat Med. 2013 May 30; 32(12):1975-94.
Score: 0.118
-
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemp Clin Trials. 2013 Nov; 36(2):642-50.
Score: 0.062
-
Uniform power method for sample size calculation in historical control studies with binary response. Control Clin Trials. 2001 Aug; 22(4):390-400.
Score: 0.027
-
Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001 Apr; 57(4 Suppl 1):205-12.
Score: 0.026
-
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000 May; 6(5):1702-10.
Score: 0.024
-
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13.
Score: 0.014
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.014
-
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009 Jul; 2(7):617-24.
Score: 0.012
-
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol. 2005 Mar 20; 23(9):1911-20.
Score: 0.009
-
Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004 Dec 15; 101(12):2837-42.
Score: 0.008
-
Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 2003 Jan 15; 95(2):165-8.
Score: 0.007
-
Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1998 Oct 21; 90(20):1514-28.
Score: 0.006
-
Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst. 1998 Feb 04; 90(3):243-5.
Score: 0.005